# US 2026/0027231 A1 · Genome editing of the kozak sequence for treating diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027231 A1
- Document ID: US20260027231A1
- Status: Published application
- Kind: A1
- Application number: 18/996,418
- Filed: 2023-08-04
- Published: 2026-01-29
- Earliest claimed: 2022-08-05
- Assignees: Universita' Degli Studi Di Trento
- Applicants: Universita' Degli Studi Di Trento
- Inventors: Alessandro QUATTRONE; Chiara AMBROSINI; Anna CERESETO; Gianluca PETRIS; Eliana DESTEFANIS; Alberto RAOSS
- Web page: https://patentgrep.com/patent/US20260027231A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/67: General methods for enhancing the expression
- C40B 40/06: Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Y 306/05005: Dynamin GTPase (3.6.5.5)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C12Y: ENZYMES

## Abstract

The present invention relates to the medical field of single-gene disorders caused by functional loss or gain of an allele. The innovative approach developed being based on editing the human genome at the level of the Kozak sequence by means of CRISPR-Cas programmable nucleases. Particularly, the present invention relates to variant Kozak sequences and related in vitro or in vivo methods for obtaining such variant Kozak sequences for therapeutic applications in the treatment of single-gene diseases caused by monoallelic losses or gains. These in vitro and in vivo methods include CRISPR-Cas homology-directed repair, CRISPR-Cas prime editing, CRISPR-Cas base editing or genome editing with other programmable RNA-guided nucleases, and the introduction of specific nucleotide conversions in the Kozak sequence of genes causative of diseases. These nucleotide conversions enhance or inhibit the translation of the mRNA produced by the gene, compensating for the functional loss or gain of one allele in the diseases.

## Claims

### Claim 1

A variant Kozak nucleotide sequence obtained by genome editing methods acting as translational modulator of a protein-encoding gene in the treatment of a disease wherein the expression of said protein is altered, wherein said variant Kozak nucleotide sequence replaces, in vitro or in vivo, the wild-type Kozak sequence.

### Claim 2 (depends on 1)

A variant Kozak nucleotide sequences according to claim 1, wherein said genome editing methods are selected from the group consisting of CRISPR-Cas homology-directed repair, CRISPR-Cas prime editing, CRISPR-Cas base editing or any other method based on programmable RNA-guided nuclease fused to effector proteins allowing for the introduction of one or more nucleotide conversions.

### Claim 3 (depends on 1)

A variant Kozak nucleotide sequence according to claim 1 wherein said translation modulator is a translation enhancer or a translation repressor.

### Claim 4 (depends on 3)

A variant Kozak nucleotide sequence according to claim 3 selected from the group consisting of SEQ ID NO:1-SEQ ID NO:58 as translation enhancers or selected from the group consisting of SEQ ID NO:61-SEQ ID NO:65 as translation repressors wherein said variant Kozak nucleotide sequences replace, in vitro or in vivo, the wild-type Kozak sequence.

### Claim 5 (depends on 4)

A method of increasing the translational efficiency of a protein-encoding gene in the treatment of haploinsufficiency diseases comprising administering to a subject in need thereof a sufficient amount of the variant Kozak nucleotide sequence according to claim 4.

### Claim 6 (depends on 5)

The method according to claim 5 wherein said haploinsufficiency disease is selected from the following disease classes: developmental disabilities, metabolic syndromes, eye disorders and hematopoietic diseases.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the developmental disability is selected from: intellectual developmental disorder, autosomal dominant 7; intellectual developmental disorder 6, with or without seizures; 2p16.3 deletion syndrome; developmental and epileptic encephalopathy 4.

### Claim 8 (depends on 6)

The method according to claim 6, wherein:
when the developmental disability is intellectual developmental disorder, autosomal dominant 7, the nucleotide sequence is selected from SEQ ID NO:1 to SEQ ID NO:3;
when the developmental disability is intellectual developmental disorder, autosomal dominant 6, with or without seizures, the nucleotide sequence is selected from SEQ ID NO:4 to SEQ ID NO:8;
when the developmental disability is chromosome 2p16.3 deletion syndrome, the nucleotide sequence is selected from SEQ ID NO:9 to SEQ ID NO:14;
when the developmental disability is developmental and epileptic encephalopathy 4, the nucleotide sequence is selected from SEQ ID NO:15 to SEQ ID NO:28.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the metabolic syndrome is selected from: maturity-onset diabetes of the young, type 3; susceptibility to obesity; lymphatic vascular defects and/or adult-onset obesity.

### Claim 10 (depends on 6)

The method according to claim 6, wherein:
when the metabolic syndrome is maturity-onset diabetes of the young, type 3, the nucleotide sequence is selected from SEQ ID NO:29 to SEQ ID NO:33;
when the metabolic syndrome is susceptibility to obesity, the nucleotide sequence is selected from SEQ ID NO;34 to SEQ ID NO:38;
when the metabolic syndrome is lymphatic vascular defects and/or adult-onset obesity, the nucleotide sequence is selected from SEQ ID NO:39 to SEQ ID NO:41.

### Claim 11 (depends on 6)

The method according to claim 6, wherein the eye disorder is selected from branchiootorenal syndrome, optic atrophy, Stickler syndrome type 1, nonsyndromic ocular.

### Claim 12 (depends on 6)

The method according to claim 6, wherein:
when the eye disorder is branchiootorenal syndrome, the nucleotide sequence is selected from SEQ ID NO:42 or SEQ ID NO:43;
when the eye disorder is optic atrophy, the nucleotide sequence is selected from SEQ ID NO:44 to SEQ ID NO:50;
when the eye disorder is Stickler syndrome type 1, nonsyndromic ocular, the nucleotide sequence is selected from SEQ ID NO:51 to SEQ ID NO:53.

### Claim 13 (depends on 6)

The method according to claim 6 wherein when the hematopoietic disease is chronic granulomatous disease, said nucleotide sequence is selected from SEQ ID NO:54 to SEQ ID NO:58.

### Claim 14

A gRNA designed to edit the wild-type Kozak sequence in order to obtain any one of the variant Kozak nucleotide sequences selected from the group SEQ ID NO:1-SEQ ID NO:58, characterized in that its targeting sequence corresponds to a target domain adjacent to a PAM sequence that is within 30 nucleotides to the ATG starting codon, either upstream or downstream.

### Claim 15 (depends on 14)

A gRNA according to claim 14 editing the wild-type Kozak sequence of NCF1 wherein the gRNA has the nucleotide sequence SEQ ID NO:59.

### Claim 16 (depends on 14)

A gRNA according to claim 14 editing the wild-type Kozak sequence of OPA1 wherein the gRNA has the nucleotide sequence SEQ ID NO:60.

### Claim 17 (depends on 14)

Vector for genome editing comprising any one of the gRNAs according to claim 14.

### Claim 18 (depends on 17)

Pharmaceutical composition comprising the vector according to claim 17, together with other suitable components for in vivo genome editing.

### Claim 19 (depends on 18)

Pharmaceutical composition according to claim 18, which is intravenously injectable.

### Claim 20 (depends on 1)

A method of treating haploinsufficiency diseases or gene duplication diseases comprising administering to a subject in need thereof a therapeutically sufficient amount of the variant Kozak nucleotide sequence according to claim 1.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the haploinsufficiency disease is selected from the group consisting of developmental disabilities, metabolic syndromes, eye disorders and hematopoietic diseases.

### Claim 22 (depends on 21)

The method according to claim 21, wherein:
when the developmental disability is intellectual developmental disorder, autosomal dominant 7, the nucleotide sequence is selected from SEQ ID NO:1 to SEQ ID NO:3;
when the developmental disability is intellectual developmental disorder, autosomal dominant 6, with or without seizures, the nucleotide sequence is selected from SEQ ID NO:4 to SEQ ID NO:8;
when the developmental disability is chromosome 2p16.3 deletion syndrome, the nucleotide sequence is selected from SEQ ID NO:9 to SEQ ID NO:14;
when the developmental disability is developmental and epileptic encephalopathy 4, the nucleotide sequence is selected from SEQ ID NO:15 to SEQ ID NO:28.

### Claim 23 (depends on 21)

The method according to claim 21, wherein:
when the metabolic syndrome is maturity-onset diabetes of the young, type 3, the nucleotide sequence is selected from SEQ ID NO:29 to SEQ ID NO:33;
when the metabolic syndrome is susceptibility to obesity, the nucleotide sequence is selected from SEQ ID NO; 34 to SEQ ID NO:38;
when the metabolic syndrome is lymphatic vascular defects and/or adult-onset obesity, the nucleotide sequence is selected from SEQ ID NO:39 to SEQ ID NO:41.

### Claim 24 (depends on 21)

The method according to claim 21, wherein:
when the eye disorder is branchiootorenal syndrome, the nucleotide sequence is selected from SEQ ID NO:42 or SEQ ID NO:43;
when the eye disorder is optic atrophy, the nucleotide sequence is selected from SEQ ID NO:44 to SEQ ID NO:50;
when the eye disorder is Stickler syndrome type 1, nonsyndromic ocular, the nucleotide sequence is selected from SEQ ID NO:51 to SEQ ID NO:53.

### Claim 25 (depends on 21)

The method according to claim 21, wherein when the hematopoietic disease is chronic granulomatous disease, said nucleotide sequence is selected from SEQ ID NO:54 to SEQ ID NO:58.

### Claim 26 (depends on 20)

The method according to claim 20, wherein the gene duplication disease is selected from the group consisting of motor and sensory neuropathies.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the motor and sensory neuropathy is Charcot-Marie-Tooth disease type 1A, the nucleotide sequence is selected from SEQ ID NO:61 to SEQ ID NO:65.
